Renalytix is an AI-enabled diagnostics company whose kidneyintelX.dkd blood test assesses the risk of kidney function decline in patients with type 2 diabetes and chronic kidney disease. In September 2025, Renalytix entered a strategic partnership with Tempus AI, Inc. (“Tempus” or “Tempus AI”) a NASDAQ-listed US-based precision medicine company, to integrate its FDA-approved, guidelines-recommended, Medicare-reimbursed kidneyintelX.dkd test into Tempus’ extensive healthcare network of physicians ....
